Literature DB >> 19879996

Development of a simple and high-yielding fed-batch process for the production of influenza vaccines.

Jamal Meghrous1, Wafaa Mahmoud, Danielle Jacob, Rick Chubet, Manon Cox, Amine A Kamen.   

Abstract

A robust and reliable GMP-compatible fed-batch process was successfully developed for the production of recombinant hemagglutinin (rHA) proteins by expresSF cells. The feeding solution, feeding strategy as well as the cell density at infection were optimized to maximize the final rHA production yields without affecting the existing rHA recovery protocol and downstream process. A simple and stable feeding solution was formulated and a rational feeding regimen designed to yield, depending on the rHA baculovirus used, between 2- and 3-fold enhancements in volumetric rHA production with increased specific productivity compared to the batch culture. Recombinant HA from fed-batch cultures could be simply recovered following cell lysis and purified through chromatographic steps. Overall, the increased rHA yield was maintained throughout the whole process. The performance, reproducibility and scalability of the fed-batch process was successfully demonstrated in 12 bioreactor runs of 2- and 10-L working volume using five different rHA encoding baculoviruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879996     DOI: 10.1016/j.vaccine.2009.10.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim; Fu-Shi Quan; Alexander Anstey; Matthew Ivory; Mark R Prausnitz; Richard W Compans; James C Birchall
Journal:  Vaccine       Date:  2010-06-08       Impact factor: 3.641

2.  Vaccine production, distribution, access, and uptake.

Authors:  Jon Smith; Marc Lipsitch; Jeffrey W Almond
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

3.  Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody.

Authors:  Huifeng Zhang; Haibin Wang; Mei Liu; Tao Zhang; Ji Zhang; Xiangjing Wang; Wensheng Xiang
Journal:  Cytotechnology       Date:  2012-08-21       Impact factor: 2.058

Review 4.  Egg-Independent Influenza Vaccines and Vaccine Candidates.

Authors:  Ilaria Manini; Claudia Maria Trombetta; Giacomo Lazzeri; Teresa Pozzi; Stefania Rossi; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2017-07-18

Review 5.  Recombinant protein vaccines produced in insect cells.

Authors:  Manon M J Cox
Journal:  Vaccine       Date:  2012-01-17       Impact factor: 3.641

Review 6.  Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production.

Authors:  Manon M J Cox
Journal:  Vaccines (Basel)       Date:  2021-12-20

7.  Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.

Authors:  Verena Lohr; Yvonne Genzel; Ingo Jordan; Dietmar Katinger; Stefan Mahr; Volker Sandig; Udo Reichl
Journal:  BMC Biotechnol       Date:  2012-10-30       Impact factor: 2.563

8.  A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

Authors:  Florian Krammer; Irina Margine; Gene S Tan; Natalie Pica; Jens C Krause; Peter Palese
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

9.  Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection.

Authors:  Karina Jawinski; Marcus Hartmann; Charanjit Singh; Ekaterina Kinnear; David C Busse; Annalisa Ciabattini; Fabio Fiorino; Donata Medaglini; Claudia Maria Trombetta; Emanuele Montomoli; Vanessa Contreras; Roger Le Grand; Celine Coiffier; Charlotte Primard; Bernard Verrier; John S Tregoning
Journal:  Front Immunol       Date:  2019-11-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.